The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with nasal ...

The China National Medical Products Administration (NMPA) has approved GSK’s Nucala (mepolizumab) as an add-on treatment with intranasal corticosteroids to treat chronic rhinosinusitis with ...

Nucala (mepolizumab), has been approved in China for treating adults with chronic rhinosinusitis with nasal polyps (CRSwNP), a condition affecting 30 million people in the country. This approval ...

GSK (GSK) announced that the China National Medical Products Administration has approved Nucala, a monoclonal antibody ... rhinosinusitis with nasal polyps, CRSwNP, for whom therapy with systemic ...

On Friday, the China National Medical Products Administration approved GSK plc (NYSE:GSK) Nucala (mepolizumab) as an add-on therapy with intranasal corticosteroids for adult patients with chronic ...

"We are delighted that Nucala has been approved in China as a treatment for CRSwNP, a chronic condition for which new and effective treatments are needed," said GSK senior vice-president and ...

Since then AZ and Teva have bought rivals to market, but if approved in CRSwNP Nucala will take on Sanofi’s Dupixent (dupilumab) which has a different mechanism of action and was FDA-approved in ...

Sanofi/Regeneron's IL-4 and IL-13 inhibitor Dupixent (dupilumab) was approved to treat CRSwNP in 2019, and was joined on the US market by GSK's IL-5 inhibitor Nucala (mepolizumab) last year.